Octagon Capital Advisors LP
All holdings · as of Dec 31, 2025
| Company | Value | % of portfolio |
|---|---|---|
| PepGen Inc. | $4.56M | 0.6% |
| Unicycive Therapeutics, Inc. | $5.77M | 0.7% |
| Corbus Pharmaceuticals Holdings, Inc.CRBP | $7.77M | 1.0% |
| Precision BioSciences, Inc. | $7.98M | 1.0% |
| Evommune, Inc.EVMN | $8.56M | 1.1% |
| DBV TECHNOLOGIES S.A.DBVT | $11.01M | 1.4% |
| BridgeBio Oncology Therapeutics, Inc.BBOT | $13.06M | 1.6% |
| Lexeo Therapeutics, Inc. | $17.13M | 2.1% |
| Pharvaris N.V. | $18.63M | 2.3% |
| CENTESSA PHARMACEUTICALS PLC | $18.76M | 2.3% |
| RAPT THERAPEUTICS INC | $19.44M | 2.4% |
| KalVista Pharmaceuticals Inc | $20.56M | 2.6% |
| BioAge Labs, Inc.BIOA | $21.14M | 2.6% |
| CIDARA THERAPEUTICS INC | $22.09M | 2.8% |
| PALISADE BIO, INC. | $22.48M | 2.8% |
| ALUMIS INC.ALMS | $24.70M | 3.1% |
| MIND MEDICINE MINDMED INC | $29.86M | 3.7% |
| Ocular Therapeutix, Inc | $31.85M | 4.0% |
| Trevi Therapeutics, Inc. | $35.24M | 4.4% |
| ARRIVENT BIOPHARMA INCAVBP | $39.66M | 5.0% |
| Kymera Therapeutics, Inc. | $41.63M | 5.2% |
| Gossamer Bio, Inc. | $43.14M | 5.4% |
| Taysha Gene Therapies, Inc.TSHA | $48.73M | 6.1% |
| Cogent Biosciences, Inc. | $83.47M | 10.5% |
| Dianthus Therapeutics, Inc. | $99.59M | 12.5% |
| ABIVAX SA | $101.95M | 12.8% |